Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

28.02.25	Lilly to participate in Leerink Partners Global Healthcare Conference (EN, Eli Lilly)
28.02.25	Eli Lilly: CHMP Issues Positive Opinion For Jaypirca - Quick Facts (RTTNews)
26.02.25	Eli Lilly And Company To Build Four Pharmaceutical Manufacturing Sites In US (RTTNews)
26.02.25	Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion (EN, Eli Lilly)
25.02.25	Liily Launches Additional Zepbound Vial Doses; Lowers Price Of Existing Doses (RTTNews)
25.02.25	Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients (EN, Eli Lilly)
18.02.25	Lilly to participate in TD Cowen's 45th Annual Health Care Conference (EN, Eli Lilly)
07.02.25	Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years (EN, Eli Lilly)
07.02.25	Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years (EN, Eli Lilly)
06.02.25	Eli Lilly Guides FY25 In Line With Estimates - Update (RTTNews)
06.02.25	Eli Lilly And Co. Q4 Profit Increases, Beats Estimates (RTTNews)
06.02.25	Lilly reports full Q4 2024 financial results and provides 2025 guidance (EN, Eli Lilly)
23.01.25	Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement (EN, Eli Lilly)
16.01.25	FDA Approves Lilly's Omvoh For Crohn's Disease Treatment (RTTNews)
15.01.25	FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease (EN, Eli Lilly)
14.01.25	Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25 (RTTNews)
14.01.25	Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance (EN, Eli Lilly)
13.01.25	Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash (RTTNews)
13.01.25	Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program (EN, Eli Lilly)
07.01.25	Lilly to participate in J.P. Morgan Healthcare Conference (EN, Eli Lilly)
23.12.24	Lilly commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk (EN, Eli Lilly)
21.12.24	FDA Approves Lilly's Zepbound To Treat Obstructive Sleep Apnea In Adults With Obesity (RTTNews)
20.12.24	FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity (EN, Eli Lilly)
18.12.24	China Approves Lilly's Kisunla For Early Symptomatic Alzheimer's Disease Treatment (RTTNews)
18.12.24	Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease (EN, Eli Lilly)
17.12.24	Eli Lilly: Egyptian Drug Authority Approves Insulin Glargine Injection Manufactured By EVA Pharma (RTTNews)
17.12.24	Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt (EN, Eli Lilly)
13.12.24	Lilly Gets Positive CHMP Opinion For Omvoh In Crohn's Disease (RTTNews)
13.12.24	Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease (EN, Eli Lilly)
11.12.24	Lilly Reports Positive Phase 3 EMBER-3 Study Data In Advanced Breast Cancer (RTTNews)
11.12.24	Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer (EN, Eli Lilly)
10.12.24	Lilly Board Approves New $15 Bln Share Repurchase Program; Hikes Dividend (RTTNews)
09.12.24	Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting (EN, Eli Lilly)
09.12.24	Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase (EN, Eli Lilly)
09.12.24	CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade (EN, Eli Lilly)
06.12.24	Lilly Announces $3 Bln Expansion Of Manufacturing Facility In Wisconsin (RTTNews)
05.12.24	Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin (EN, Eli Lilly)
04.12.24	Lilly Says Zepbound Provided 47% Higher Relative Weight Loss Compared To Wegovy In SURMOUNT-5 Study (RTTNews)
04.12.24	Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% (EN, Eli Lilly)
19.11.24	Lilly announces changes on board of directors (EN, Eli Lilly)
18.11.24	Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose (EN, Eli Lilly)
18.11.24	Incyclix Bio And Eli Lilly To Evaluate INX-315, Verzenio, And Fulvestrant In HR+/HER2- Breast Cancer (RTTNews)
17.11.24	Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity (RTTNews)
16.11.24	Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity (EN, Eli Lilly)
15.11.24	Lilly Statement on New 340B Litigation (EN, Eli Lilly)
13.11.24	Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks (EN, Eli Lilly)
05.11.24	Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (EN, Eli Lilly)
01.11.24	Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium (EN, Eli Lilly)
30.10.24	Lilly Cuts FY24 Earnings, Revenue Outlook After Q3 Misses Street; Stock Down In Pre-market - Update (RTTNews)
30.10.24	Eli Lilly And Co. Q3 Earnings Summary (RTTNews)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	592.40	6.82 %	K V
Kuehne+Nagel Int	210.10	2.24 %	K V
Holcim	101.60	1.76 %	K V
ABB	48.92	0.53 %	K V
Part Grp Hldg	1’328.50	0.34 %	K V
Lonza Grp	570.60	-1.38 %	K V
Alcon	82.14	-1.68 %	K V
Swiss Re	144.80	-2.06 %	K V
CieFinRichemont	174.30	-4.23 %	K V
Sonova Hldg	273.40	-5.50 %	K V

mehr

06.03.25		Angespannte Stimmung in New York: Dow Jones gibt letztendlich nach
06.03.25		STOXX 50 aktuell: STOXX 50 schlussendlich in der Verlustzone
06.03.25		Merck-Aktie im Aufwind: Plan nach Aufschung 2024 weiter profitabel zu wachsen
06.03.25		Schwacher Handel: STOXX 50 sackt am Donnerstagnachmittag ab
06.03.25		Börse Europa: STOXX 50 gibt am Mittag nach
06.03.25		Merck-Aktie: Bernstein Research vergibt Bewertung
06.03.25		Neue Analyse: Goldman Sachs Group Inc. bewertet Merck-Aktie mit Buy
06.03.25		Investment-Tipp: So bewertet Deutsche Bank AG die Novartis-Aktie